L-methylfolate shows promise for major depressive disorder patients
L-methylfolate could help patients who do not respond to selective serotonin reuptake inhibitor antidepressants.
Findings of a clinical trial suggest that adjunctive L-methylfolate could prove effective in treating certain groups of patients with major depressive disorder (MDD).
Experimentation indicates that it could be an alternative for those who are not benefiting from expected outcomes through prescription of selective serotonin reuptake inhibitors (SSRIs).
Researchers recruited 75 outpatients with this drug resistance and analysed the effects of a 15 mg per day L-methylfolate treatment against a placebo in a randomised, controlled trial.
Cross-referencing results from the Hamilton Depression Rating Scale (HDRS-17) showed a significant lessening of symptoms among participants who took L-methylfolate.
Obese patients and those with biomarkers indicating inflammation benefited most substantially, suggesting that the drug will have widespread clinical application.
Psychiatric mental health nurse practitioner Gail Dawson said: "Now we can provide an additional option for people struggling with residual symptoms of depression."
The healthcare expert will present these findings at the American Association of Nurse Practitioners (AANP) National Conference in Las Vegas between June 20th and 22th.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance